218 related articles for article (PubMed ID: 29626645)
1. Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer.
Afkham A; Aghebati-Maleki L; Siahmansouri H; Sadreddini S; Ahmadi M; Dolati S; Afkham NM; Akbarzadeh P; Jadidi-Niaragh F; Younesi V; Yousefi M
Pharmacol Rep; 2018 Jun; 70(3):418-425. PubMed ID: 29626645
[TBL] [Abstract][Full Text] [Related]
2. Chitosan nanoparticles as a dual drug/siRNA delivery system for treatment of colorectal cancer.
Sadreddini S; Safaralizadeh R; Baradaran B; Aghebati-Maleki L; Hosseinpour-Feizi MA; Shanehbandi D; Jadidi-Niaragh F; Sadreddini S; Kafil HS; Younesi V; Yousefi M
Immunol Lett; 2017 Jan; 181():79-86. PubMed ID: 27916629
[TBL] [Abstract][Full Text] [Related]
3. Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line.
Siahmansouri H; Somi MH; Babaloo Z; Baradaran B; Jadidi-Niaragh F; Atyabi F; Mohammadi H; Ahmadi M; Yousefi M
J Pharm Pharmacol; 2016 Sep; 68(9):1119-30. PubMed ID: 27350211
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M
Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407
[TBL] [Abstract][Full Text] [Related]
5. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
6. SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line.
Seifi-Najmi M; Hajivalili M; Safaralizadeh R; Sadreddini S; Esmaeili S; Razavi R; Ahmadi M; Mikaeili H; Baradaran B; Shams-Asenjan K; Yousefi M
Cell Mol Biol (Noisy-le-grand); 2016 Sep; 62(11):87-94. PubMed ID: 27755958
[TBL] [Abstract][Full Text] [Related]
7. Oral delivery of nanoparticles containing anticancer SN38 and hSET1 antisense for dual therapy of colon cancer.
Dinarvand M; Kiani M; Mirzazadeh F; Esmaeili A; Mirzaie Z; Soleimani M; Dinarvand R; Atyabi F
Int J Biol Macromol; 2015; 78():112-21. PubMed ID: 25858880
[TBL] [Abstract][Full Text] [Related]
8. MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery.
Sayari E; Dinarvand M; Amini M; Azhdarzadeh M; Mollarazi E; Ghasemi Z; Atyabi F
Int J Pharm; 2014 Oct; 473(1-2):304-15. PubMed ID: 24905777
[TBL] [Abstract][Full Text] [Related]
9. Tetrac-decorated chitosan-coated PLGA nanoparticles as a new platform for targeted delivery of SN38.
Alibolandi M; Amel Farzad S; Mohammadi M; Abnous K; Taghdisi SM; Kalalinia F; Ramezani M
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1003-1014. PubMed ID: 29806500
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of hypoxia inducible factor-1α small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells.
Chen Y; Sun L; Guo D; Wu Z; Chen W
J Gene Med; 2017 Dec; 19(12):. PubMed ID: 29106062
[TBL] [Abstract][Full Text] [Related]
11. Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy.
Bi Y; Lee RJ; Wang X; Sun Y; Wang M; Li L; Li C; Xie J; Teng L
Int J Nanomedicine; 2018; 13():5811-5822. PubMed ID: 30323583
[TBL] [Abstract][Full Text] [Related]
12. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
13. Optimization of chitosan nanoparticles as an anti-HIV siRNA delivery vehicle.
Iranpur Mobarakeh V; Modarressi MH; Rahimi P; Bolhassani A; Arefian E; Atyabi F; Vahabpour R
Int J Biol Macromol; 2019 May; 129():305-315. PubMed ID: 30738164
[TBL] [Abstract][Full Text] [Related]
14. Chitosan-based hybrid nanocomplex for siRNA delivery and its application for cancer therapy.
Ki MH; Kim JE; Lee YN; Noh SM; An SW; Cho HJ; Kim DD
Pharm Res; 2014 Dec; 31(12):3323-34. PubMed ID: 24858398
[TBL] [Abstract][Full Text] [Related]
15. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
[TBL] [Abstract][Full Text] [Related]
17. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of Fe
Arami S; Rashidi MR; Mahdavi M; Fathi M; Entezami AA
Hum Exp Toxicol; 2017 Mar; 36(3):227-237. PubMed ID: 27162247
[TBL] [Abstract][Full Text] [Related]
19. Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery.
Sharma K; Somavarapu S; Colombani A; Govind N; Taylor KM
Int J Pharm; 2013 Oct; 455(1-2):241-7. PubMed ID: 23876499
[TBL] [Abstract][Full Text] [Related]
20. Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression.
Salimifard S; Karoon Kiani F; Sadat Eshaghi F; Izadi S; Shahdadnejad K; Masjedi A; Heydari M; Ahmadi A; Hojjat-Farsangi M; Hassannia H; Mohammadi H; Boroumand-Noughabi S; Keramati MR; Jadidi-Niaragh F
Life Sci; 2020 Nov; 260():118423. PubMed ID: 32941896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
